BioCentury | Mar 16, 2009
Company News

Genavia Therapeutics Ltd., Origen Therapeutics Inc., Symphogen deal

...Genavia and is eligible for milestones and royalties. Genavia Therapeutics Ltd. , Auckland, New Zealand Origen Therapeutics Inc....
BioCentury | Oct 8, 2007
Company News

Origen Therapeutics Inc., U.S. Department of Commerce infectious, cancer, antibodies news

...company plans to first develop polyclonal antibodies to treat antibiotic-resistant infections in intensive care units. Origen Therapeutics Inc....
BioCentury | Sep 10, 2001
Company News

Origen Therapeutics Inc. other research news

...for production of recipient embryos that yield high-grade chimeras when combined with donor ES cells. Origen Therapeutics Inc....
BioCentury | Aug 6, 2001
Company News

Embrex, Origen Therapeutics Inc. other research news

...embryonic stem (ES) cells and in ovo technology. Embrex Inc. (EMBX), Research Triangle Park, NC Origen Therapeutics Inc....
BioCentury | Jan 2, 2001
Company News

AviGenics, Geron, Origen Therapeutics Inc. deal

...the options are exercised. AviGenics Inc. , Athens, Ga. Geron Corp. (GERN), Menlo Park, Calif. Origen Therapeutics Inc....
BioCentury | Dec 20, 2000
Company News

Geron grants licenses to develop cloned poultry

...AviGenics (Athens, Ga.) and Origen Therapeutics (Burlingame, Calif.) received options to acquire non-exclusive worldwide licenses to GERN's...
BioCentury | Sep 11, 2000
Company News

Origen Therapeutics Inc. scientific advisory board update

Origen Therapeutics Inc. , Burlingame, Calif. Business: Agbio/Veterinary/Environmental Appointed: Claudio Daniel Stern, professor and chairman of the department of genetics and development and professor in the Center for Neurobiology and Behavior at Columbia University WIR Staff...
BioCentury | Jul 24, 2000
Company News

Origen Therapeutics Inc. other research news

...development of avian germline chimeras compared to the use of later stage (stage X) embryos. Origen Therapeutics Inc....
BioCentury | Jun 12, 2000
Company News

Embrex, Origen Therapeutics Inc. deal

...companies will contribute resources equally to the collaboration. Embrex Inc. (EMBX), Research Triangle Park, N.C. Origen Therapeutics Inc....
BioCentury | May 11, 1998
Emerging Company Profile

Origen Therapeutics Inc.

Origen Therapeutics Inc. South San Francisco, Calif. Technology: Avian stem cells to improve poultry and produce human therapeutics in eggs Disease focus: NA Clinical status: NA Founded: 1997 by Michael West and Karen Chapman Corporate...
Items per page:
1 - 10 of 13
BioCentury | Mar 16, 2009
Company News

Genavia Therapeutics Ltd., Origen Therapeutics Inc., Symphogen deal

...Genavia and is eligible for milestones and royalties. Genavia Therapeutics Ltd. , Auckland, New Zealand Origen Therapeutics Inc....
BioCentury | Oct 8, 2007
Company News

Origen Therapeutics Inc., U.S. Department of Commerce infectious, cancer, antibodies news

...company plans to first develop polyclonal antibodies to treat antibiotic-resistant infections in intensive care units. Origen Therapeutics Inc....
BioCentury | Sep 10, 2001
Company News

Origen Therapeutics Inc. other research news

...for production of recipient embryos that yield high-grade chimeras when combined with donor ES cells. Origen Therapeutics Inc....
BioCentury | Aug 6, 2001
Company News

Embrex, Origen Therapeutics Inc. other research news

...embryonic stem (ES) cells and in ovo technology. Embrex Inc. (EMBX), Research Triangle Park, NC Origen Therapeutics Inc....
BioCentury | Jan 2, 2001
Company News

AviGenics, Geron, Origen Therapeutics Inc. deal

...the options are exercised. AviGenics Inc. , Athens, Ga. Geron Corp. (GERN), Menlo Park, Calif. Origen Therapeutics Inc....
BioCentury | Dec 20, 2000
Company News

Geron grants licenses to develop cloned poultry

...AviGenics (Athens, Ga.) and Origen Therapeutics (Burlingame, Calif.) received options to acquire non-exclusive worldwide licenses to GERN's...
BioCentury | Sep 11, 2000
Company News

Origen Therapeutics Inc. scientific advisory board update

Origen Therapeutics Inc. , Burlingame, Calif. Business: Agbio/Veterinary/Environmental Appointed: Claudio Daniel Stern, professor and chairman of the department of genetics and development and professor in the Center for Neurobiology and Behavior at Columbia University WIR Staff...
BioCentury | Jul 24, 2000
Company News

Origen Therapeutics Inc. other research news

...development of avian germline chimeras compared to the use of later stage (stage X) embryos. Origen Therapeutics Inc....
BioCentury | Jun 12, 2000
Company News

Embrex, Origen Therapeutics Inc. deal

...companies will contribute resources equally to the collaboration. Embrex Inc. (EMBX), Research Triangle Park, N.C. Origen Therapeutics Inc....
BioCentury | May 11, 1998
Emerging Company Profile

Origen Therapeutics Inc.

Origen Therapeutics Inc. South San Francisco, Calif. Technology: Avian stem cells to improve poultry and produce human therapeutics in eggs Disease focus: NA Clinical status: NA Founded: 1997 by Michael West and Karen Chapman Corporate...
Items per page:
1 - 10 of 13